Project Details


PROJECT SUMMARY The pathophysiology of Alzheimer’s disease (AD) remains unclear. Amyloid plaques are surrounded by reactive astrocytes and microglia, forming glial nets that affect amyloid spreading and inflammatory milieu. However, the mechanisms of inter-glial communication in glial nets are poorly understood. Our recent integrated network analysis of -omics data from late-onset AD patients identified the axon guidance receptor Plexin-B1 as a hub gene in an astrocyte-specific subnetwork. We have confirmed that Plexin-B1 is predominantly expressed in astrocytes and that it is upregulated in glial nets of AD patients. Remarkably, our pilot study with an amyloidogenic mouse model of AD showed that Plexin-B1 deletion markedly altered the structure of peri-plaque glial nets. Plexin-B1 deletion resulted in attenuated astrocyte reactivity, reduced cellular spacing of glial nets, and a higher coverage of plaques by microglia, leading to a shift of plaques to a dense core type. These changes of glial nets were associated with an overall reduction in plaque burden and neuritic dystrophy. Here we will expand our preliminary studies to further test the central hypothesis that glial activation and cellular interactions in glial nets, as regulated by Plexin-B1, affect amyloid aggregates and neurotoxicity in AD. Blocking Plexin-B1 may thus present a new opportunity to attenuate astrocyte reactivity in glial nets, reducing amyloid burden and neuroinflammation, thereby slowing down AD progression. In Aim 1, we aim to build cell type-specific glial signaling networks in AD, and to identify Plexin-B1-mediated gene modules in glial nets. We will analyze single cell transcriptomic data from both AD patients and AD mice (with and without Plexin-B1 deletion) to define coregulated gene networks in reactive astrocytes and activated microglia that are associated with Plexin-B1 signaling. In Aim 2, we will carry out a series of functional assays in glial cultures to study the role of Plexin-B1 in mediating astrocyte activation upon amyloid challenge. Human iPSC-derived astrocytes with Plexin-B1 deletion by CRISPR-Cas will be compared to primary astrocytes from Plexin-B1 mutant mice. We will then model in astrocyte/microglia co-cultures glial interactions in response to amyloid challenge in dependence of Plexin- B1. In Aim 3, we will conduct in vivo studies using mouse AD models to investigate in detail the impact of Plexin- B1 deletion on glial nets, plaque deposition, neuronal function and cognitive performance. Both an amyloidogenic and a tauopathy model of AD will be evaluated at early and advanced stages. We expect to demonstrate that Plexin-B1 deletion leads to attenuated astrocyte reactivity in glial nets, reduced cellular spacing, increased microglial coverage of amyloid plaques, and a shift to dense-core plaques and thus less neurotoxicity, as indicated by pilot data. Altogether, our study will provide new insights into the contribution of glial nets and Plexin- B1 to the neurodegenerative processes in AD, thus providing new therapeutic angles.
Effective start/end date5/05/2230/04/25


  • National Institute on Aging: $1,800,027.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.